Drugs / Matuzumab
last change Dec 2010 re-read 2 minutes ago

Matuzumab

also known as EMD 72000

Monoclonal antibody targets EGFR

Developed for
esophageal cancer · gastric cancer · non-small cell lung carcinoma · ovarian cancer
Investigated by
EMD Serono · Merck KGaA, Darmstadt, Germany

Trials 4 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00113581 Oct 2002 → May 2006 esophageal cancer, gastric cancer Merck KGaA, Darmstadt, Germany Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00215644 Aug 2005 → Jul 2008 esophageal cancer, gastric cancer Merck KGaA, Darmstadt, Germany Completed No outcome recorded
Phase 2 NCT00111839 May 2005 → Jul 2007 non-small cell lung carcinoma EMD Serono Completed No outcome recorded
Phase 2 NCT00073541 Apr 2003 → Mar 2004 ovarian cancer EMD Serono Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as matuzumab “A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.” PMID 17126894 Nov 2006
3

NCT00111839

NCT00215644

NCT00113581

Known as EMD 72000 “This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort...” NCT00111839
3

“A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.” PMID 17126894 Nov 2006

EMD 72000 (matuzumab)” NCT00113581

NCT00073541

Action Inhibit “EMD 72000 blocks a factor found on the surface of many cancer cells.” NCT00073541
Modality Monoclonal antibody “a humanized anti-EGFR monoclonal antibodyPMID 17126894 Nov 2006
Route Intravenous “Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.” NCT00111839
Target EGFR “the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab” PMID 20978446 Dec 2010